Decolonization (medicine)

Last updated

Decolonization
Other namesBacterial decolonization
Specialty Infectious disease, infection control

Decolonization, also bacterial decolonization, is a medical intervention that attempts to rid a patient of an antimicrobial resistant pathogen, [1] such as methicillin-resistant Staphylococcus aureus (MRSA) or antifungal-resistant Candida . [2]

Contents

By pre-emptively treating patients who have become colonized with an antimicrobial resistant organism, the likelihood of the patient going on to develop life-threatening healthcare-associated infections is reduced. Common sites of bacterial colonization include the nasal passage, groin, oral cavity and skin. [1]

History

In cooperation with the Centers for Disease Control and Prevention (CDC), the Chicago Antimicrobial Resistance and Infection Prevention Epicenter (C-PIE), Harvard/Irvine Bi-Coastal Epicenter, and Washington University and Barnes Jewish County (BJC) Center for Prevention of Healthcare-Associated Infections conducted a study to test different strategies to prevent and decrease the rate of healthcare-associated infections (HAIs). [3] REDUCE MRSA, which stands for Randomized Evaluation of Decolonization vs. Universal Clearance to Eliminate methicillin-resistant Staphylococcus aureus (MRSA), was completed in September 2011. [3] This study determined decolonization with chlorhexidine and mupirocin of all patients without screening was the most effective method of reducing the presence of MRSA and the overall number of bloodstream infections. [3] [4]

Medical uses

Decolonization is used to reduce rates of infections caused by MRSA. Staphylococcus aureus(S. aureus) is a common cause of hospital related infections, including bloodstream infections and infections of the heart and bone. [5] Additionally, increasing cases of methicillin-susceptible S. aureus (MSSA) and MRSA pose a new challenge as these strains are difficult or impossible to treat with standard antibiotic regimens. Because of the prevalence of S. aureus within the general population and significant number of severe infections caused by this bacteria, decolonization protocols have been implemented in many hospital networks to decrease MRSA infections. [4] By using disinfectants over an extended period of time, decolonization decreases or minimizes patient bacterial load.[ citation needed ]

Technique

There are several decolonization regimens currently used for MRSA decolonization. Targeted decolonization involves screening patients for MRSA then isolating and implementing decolonization protocols only for patients who test positive for MRSA. On the other hand, universal decolonization involves no screening and decolonization for all patients in a given hospital setting or department. [3]

Products used for decolonization typically involve chlorhexidine rinses for bathing or showering, a mouthwash to clean the oral cavity, and a nasal spray containing mupirocin. It is important to include a mouthwash and nasal spray as individuals commonly carry MRSA in the nose, mouth, and throat. Chlorhexidine is a disinfectant that is used to disinfect skin prior to surgery, [6] surgical instrument sterilization, and in hand disinfectants in healthcare settings. In the mouthwash form, it is commonly used for gingivitis.[ citation needed ] Mupirocin is a topical antibiotic commonly used for superficial skin infections and has been approved by the FDA nasal decolonization. [7] [8] Though these are the most commonly used products, there are a number of alternative antibiotics and antiseptics, like povidone-iodine, that are used in decolonization.[ citation needed ]

Typically, patients use chlorhexidine shampoo or body wash daily and mupirocin nasal spray twice daily. The duration of product use for optimal effect is still being studied, but the most widely studied regimen recommends use of the products as mentioned previously for five days twice a month over a sixth month period. [4] There is limited data supporting decolonization or recommendations of duration of decolonization in outpatient settings. [9]

Risks and complications

Decolonization is a relatively safe medical intervention. Local skin irritation is the most common side effect. [4]

See also

Related Research Articles

<i>Staphylococcus aureus</i> Species of Gram-positive bacterium

Staphylococcus aureus is a Gram-positive spherically shaped bacterium, a member of the Bacillota, and is a usual member of the microbiota of the body, frequently found in the upper respiratory tract and on the skin. It is often positive for catalase and nitrate reduction and is a facultative anaerobe that can grow without the need for oxygen. Although S. aureus usually acts as a commensal of the human microbiota, it can also become an opportunistic pathogen, being a common cause of skin infections including abscesses, respiratory infections such as sinusitis, and food poisoning. Pathogenic strains often promote infections by producing virulence factors such as potent protein toxins, and the expression of a cell-surface protein that binds and inactivates antibodies. S. aureus is one of the leading pathogens for deaths associated with antimicrobial resistance and the emergence of antibiotic-resistant strains, such as methicillin-resistant S. aureus (MRSA), is a worldwide problem in clinical medicine. Despite much research and development, no vaccine for S. aureus has been approved.

Methicillin-resistant <i>Staphylococcus aureus</i> Bacterium responsible for difficult-to-treat infections in humans

Methicillin-resistant Staphylococcus aureus (MRSA) is a group of gram-positive bacteria that are genetically distinct from other strains of Staphylococcus aureus. MRSA is responsible for several difficult-to-treat infections in humans. It caused more than 100,000 deaths worldwide attributable to antimicrobial resistance in 2019.

<span class="mw-page-title-main">Methicillin</span> Antibiotic medication

Methicillin (USAN), also known as meticillin (INN), is a narrow-spectrum β-lactam antibiotic of the penicillin class.

<span class="mw-page-title-main">Hospital-acquired infection</span> Infection that is acquired in a hospital or other health care facility

A hospital-acquired infection, also known as a nosocomial infection, is an infection that is acquired in a hospital or other healthcare facility. To emphasize both hospital and nonhospital settings, it is sometimes instead called a healthcare-associated infection. Such an infection can be acquired in a hospital, nursing home, rehabilitation facility, outpatient clinic, diagnostic laboratory or other clinical settings. A number of dynamic processes can bring contamination into operating rooms and other areas within nosocomial settings. Infection is spread to the susceptible patient in the clinical setting by various means. Healthcare staff also spread infection, in addition to contaminated equipment, bed linens, or air droplets. The infection can originate from the outside environment, another infected patient, staff that may be infected, or in some cases, the source of the infection cannot be determined. In some cases the microorganism originates from the patient's own skin microbiota, becoming opportunistic after surgery or other procedures that compromise the protective skin barrier. Though the patient may have contracted the infection from their own skin, the infection is still considered nosocomial since it develops in the health care setting. Nosocomial infection tends to lack evidence that it was present when the patient entered the healthcare setting, thus meaning it was acquired post-admission.

<span class="mw-page-title-main">Fusidic acid</span> Antibiotic

Fusidic acid, sold under the brand names Fucidin among others, is an steroid antibiotic that is often used topically in creams or ointments and eyedrops but may also be given systemically as tablets or injections.
As of October 2008, the global problem of advancing antimicrobial resistance has led to a renewed interest in its use.

Vancomycin-resistant <i>Staphylococcus aureus</i> Antibiotica resistant bacteria

Vancomycin-resistant Staphylococcus aureus (VRSA) are strains of Staphylococcus aureus that have acquired resistance to the glycopeptide antibiotic vancomycin. Bacteria can acquire resistant genes either by random mutation or through the transfer of DNA from one bacterium to another. Resistance genes interfere with the normal antibiotic function and allow a bacteria to grow in the presence of the antibiotic. Resistance in VRSA is conferred by the plasmid-mediated vanA gene and operon. Although VRSA infections are uncommon, VRSA is often resistant to other types of antibiotics and a potential threat to public health because treatment options are limited. VRSA is resistant to many of the standard drugs used to treat S. aureus infections. Furthermore, resistance can be transferred from one bacterium to another.

Screening culture is a type a medical test that is done to find an infection. Screening cultures are often performed to find infections that do not have signs and symptoms.

<span class="mw-page-title-main">Cefoxitin</span> Chemical compound

Cefoxitin is a second-generation cephamycin antibiotic developed by Merck & Co., Inc. from Cephamycin C in the year following its discovery, 1972. It was synthesized in order to create an antibiotic with a broader spectrum. It is often grouped with the second-generation cephalosporins. Cefoxitin requires a prescription and as of 2010 is sold under the brand name Mefoxin by Bioniche Pharma, LLC. The generic version of cefoxitin is known as cefoxitin sodium.

Lysostaphin is a Staphylococcus simulans metalloendopeptidase. It can function as a bacteriocin (antimicrobial) against Staphylococcus aureus.

<span class="mw-page-title-main">Dalbavancin</span> Antibiotic used to treat MRSA

Dalbavancin, sold under the brand names Dalvance in the US and Xydalba in the EU among others, is a second-generation lipoglycopeptide antibiotic medication. It belongs to the same class as vancomycin, the most widely used and one of the treatments available to people infected with methicillin-resistant Staphylococcus aureus (MRSA).

<span class="mw-page-title-main">Staphylococcal infection</span> Medical condition

A staphylococcal infection or staph infection is an infection caused by members of the Staphylococcus genus of bacteria.

mecA is a gene found in bacterial cells which allows them to be resistant to antibiotics such as methicillin, penicillin and other penicillin-like antibiotics.

<span class="mw-page-title-main">Arbekacin</span> Antibiotic

Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA). Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators. It has been registered and marketed in Japan since 1990 under the trade name Habekacin. Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.

<span class="mw-page-title-main">Bullous impetigo</span> Medical condition

Bullous impetigo is a bacterial skin infection caused by Staphylococcus aureus that results in the formation of large blisters called bullae, usually in areas with skin folds like the armpit, groin, between the fingers or toes, beneath the breast, and between the buttocks. It accounts for 30% of cases of impetigo, the other 70% being non-bullous impetigo.

<span class="mw-page-title-main">Sophoraflavanone G</span> Chemical compound

Sophoraflavanone G is a volatile phytoncide, released into the atmosphere, soil and ground water, by members of the Sophora genus. Sophora pachycarpa, and Sophora exigua; all found to grow within the United States in a variety of soil types, within temperate conditions, no lower than 0 °F. Sophoraflavanone G is released in order to protect the plant against harmful protozoa, bacteria, and fungi. Sophoraflavanone G, also called kushenin, is a flavonoid compound.

An antimicrobial surface is coated by an antimicrobial agent that inhibits the ability of microorganisms to grow on the surface of a material. Such surfaces are becoming more widely investigated for possible use in various settings including clinics, industry, and even the home. The most common and most important use of antimicrobial coatings has been in the healthcare setting for sterilization of medical devices to prevent hospital associated infections, which have accounted for almost 100,000 deaths in the United States. In addition to medical devices, linens and clothing can provide a suitable environment for many bacteria, fungi, and viruses to grow when in contact with the human body which allows for the transmission of infectious disease.

ESKAPE is an acronym comprising the scientific names of six highly virulent and antibiotic resistant bacterial pathogens including: Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp. The acronym is sometimes extended to ESKAPEE to include Escherichia coli. This group of Gram-positive and Gram-negative bacteria can evade or 'escape' commonly used antibiotics due to their increasing multi-drug resistance (MDR). As a result, throughout the world, they are the major cause of life-threatening nosocomial or hospital-acquired infections in immunocompromised and critically ill patients who are most at risk. P. aeruginosa and S. aureus are some of the most ubiquitous pathogens in biofilms found in healthcare. P. aeruginosa is a Gram-negative, rod-shaped bacterium, commonly found in the gut flora, soil, and water that can be spread directly or indirectly to patients in healthcare settings. The pathogen can also be spread in other locations through contamination, including surfaces, equipment, and hands. The opportunistic pathogen can cause hospitalized patients to have infections in the lungs, blood, urinary tract, and in other body regions after surgery. S. aureus is a Gram-positive, cocci-shaped bacterium, residing in the environment and on the skin and nose of many healthy individuals. The bacterium can cause skin and bone infections, pneumonia, and other types of potentially serious infections if it enters the body. S. aureus has also gained resistance to many antibiotic treatments, making healing difficult. Because of natural and unnatural selective pressures and factors, antibiotic resistance in bacteria usually emerges through genetic mutation or acquires antibiotic-resistant genes (ARGs) through horizontal gene transfer - a genetic exchange process by which antibiotic resistance can spread.

Kerry L. LaPlante is an American pharmacist, academic and researcher. She is the Dean at the University of Rhode Island College of Pharmacy. She is a Professor of Pharmacy and former department Chair of the Department of Pharmacy Practice at the University of Rhode Island, an Adjunct Professor of Medicine at Brown University, an Infectious Diseases Pharmacotherapy Specialist, and the Director of the Rhode Island Infectious Diseases Fellowship and Research Programs at the Veterans Affairs Medical Center in Providence, Rhode Island.

MRSA ST398 is a specific strain of Methicillin-resistant Staphylococcus aureus (MRSA). Staphylococcus aureus is a gram-positive, spherical bacterium that can cause a range of infections in humans and animals. And Methicillin-resistant Staphylococcus aureus (MRSA) is a bacterium that is resistant to many antibiotics. The abbreviation "ST" in MRSA ST398 refers to the sequence type of the bacterium. MRSA ST398 is a clonal complex 398 (CC398). This means that the strain had emerged in a human clinic, without any obvious or understandable causes. MRSA ST398, a specific strain of MRSA, is commonly found in livestock, and can cause infections in humans who come into contact with infected animals.

Antimicrobial photodynamic therapy (aPDT), also referred to as photodynamic inactivation (PDI), photodisinfection (PD), or photodynamic antimicrobial chemotherapy (PACT), is a photochemical antimicrobial method that has been studied for over a century. Supported by in vitro,in vivo and clinical studies, aPDT offers a treatment option for broad-spectrum infections, particularly in the context of rising antimicrobial resistance. Its multi-target mode of action allows aPDT to be a viable therapeutic strategy against drug-resistant microorganisms. The procedure involves the application of photosensitizing compounds, also called photoantimicrobials, which, upon activation by light, generate reactive oxygen species (ROS). These ROS lead to the oxidation of cellular components of a wide array of microbes, including pathogenic bacteria, fungi, protozoa, algae, and viruses.

References

  1. 1 2 Septimus, Edward J.; Schweizer, Marin L. (27 January 2016). "Decolonization in Prevention of Health Care-Associated Infections". Clinical Microbiology Reviews. 29 (2): 201–222. doi:10.1128/CMR.00049-15. PMC   4786886 . PMID   26817630.
  2. ↑ "Antifungal Resistance | Fungal Diseases". CDC . 25 January 2019. Retrieved 10 April 2019.
  3. 1 2 3 4 "REDUCE MRSA | HAI Prevention Epicenters Program". CDC . 13 February 2019. Retrieved 16 September 2022.
  4. 1 2 3 4 Huang, S.S.; Singh, R.; McKinnell, J.A.; Park, S.; Gombosev, A.; Eells, S.J.; Gillen, D.L.; Kim, D.; Rashid, S.; Macias-Gil, R.; Bolaris, M.A.; Tjoa, T.; Cao, C.; Hong, S.S.; Lequieu, J. (14 February 2019). "Decolonization to Reduce Postdischarge Infection Risk among MRSA Carriers". The New England Journal of Medicine. 380 (7): 638–650. doi:10.1056/NEJMoa1716771. ISSN   0028-4793. PMC   6475519 . PMID   30763195.
  5. ↑ Lepelletier, Didier; Maillard, Jean Yves; Pozzetto, Bruno; Simon, Anne (20 August 2020). "Povidone Iodine: Properties, Mechanisms of Action, and Role in Infection Control and Staphylococcus aureus Decolonization". Antimicrobial Agents and Chemotherapy. 64 (9): e00682–20. doi:10.1128/AAC.00682-20. ISSN   0066-4804. PMC   7449185 . PMID   32571829.
  6. ↑ "Chlorhexidine (Topical Application Route) Proper Use". Mayo Clinic . Retrieved 28 March 2024.
  7. ↑ "Mupirocin Monograph for Professionals". Drugs.com. Retrieved 16 September 2022.
  8. ↑ Mehta, Sapna; Hadley, Scott; Hutzler, Lorraine; Slover, James; Phillips, Michael; Bosco, Joseph A. (July 2013). "Impact of Preoperative MRSA Screening and Decolonization on Hospital-acquired MRSA Burden". Clinical Orthopaedics and Related Research. 471 (7): 2367–2371. doi:10.1007/s11999-013-2848-3. ISSN   0009-921X. PMC   3676612 . PMID   23423618.
  9. ↑ Simor, Andrew E.; Phillips, Elizabeth; McGeer, Allison; Konvalinka, Ana; Loeb, Mark; Devlin, H. Rosalyn; Kiss, Alex (15 January 2007). "Randomized Controlled Trial of Chlorhexidine Gluconate for Washing, Intranasal Mupirocin, and Rifampin and Doxycycline Versus No Treatment for the Eradication of Methicillin-Resistant Staphylococcus aureus Colonization". Clinical Infectious Diseases. 44 (2): 178–185. doi: 10.1086/510392 . ISSN   1537-6591. PMID   17173213. S2CID   21411476.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.